TCRR - TCR2 Therapeutics EPS beats by $0.14 March, 30 2020 06:53 AM TCR2 Therapeutics Inc. TCR2 Therapeutics (NASDAQ:TCRR): Q4 GAAP EPS of -$0.54 beats by $0.14.Cash and cash equivalents of $65.3MPress ReleaseMore news on: TCR2 Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, ,